Aurora SFC Systems announced that it has successfully closed a Series B venture capital financing.
Aurora SFC Systems announced that it has successfully closed a Series B venture capital financing. The round was led by Aphelion Capital with participation from California Technology Partners, the Arbor Group, and several prominent Silicon Valley investors. The new capital will be used to accelerate the company’s growth in all segments of the business with a particular focus on market and product development.
Aurora SFC was founded in 2007 by Dr. Terry Berger. This new funding continues the upward trajectory of Aurora SFC that was highlighted by the announcement at Pittcon 2010 of an OEM agreement that allows Agilent Technologies to incorporate Aurora’s SFC Fusion A5 instrument into a new Agilent SFC system.
“This investment marks a significant milestone for Aurora SFC Systems and is a strong endorsement of our strategy and execution. We are proud of our technology innovations, our partnership with Agilent, and we greatly appreciate the growing acceptance of our analytical SFC products by our loyal customers” said Dr. Berger, Founder and Chief Science Office. “We are pleased to have the support of this stellar investment group, given their strong track record and deep experience in working with emerging growth companies to achieve success.”
Assessing Safety of Medications During Pregnancy and Breastfeeding with LC–MS/MS
Published: April 8th 2025 | Updated: April 8th 2025Researchers conducted a study on medications used in psychiatry and neurology during the perinatal period, assessing how antiepileptic drugs (AEDs) affect placental functions, including transport mechanisms, nutrient transport, and trophoblast differentiation. Several quantitative methods, such as those for antianxiety and hypnotic drugs, were established to evaluate the safety of pharmacotherapy during breastfeeding using liquid chromatography-tandem mass spectrometry (LC–MS/MS).